KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLong-Term Debt IssuancesLong-Term Debt RepaymentsR&D In ProcessShares IssuedShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

AbbVie (ABBV) EBIAT (2016 - 2025)

Historic EBIAT for AbbVie (ABBV) over the last 14 years, with Q3 2025 value amounting to $188.0 million.

  • AbbVie's EBIAT fell 8797.95% to $188.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 billion, marking a year-over-year decrease of 5330.34%. This contributed to the annual value of $4.3 billion for FY2024, which is 1204.6% down from last year.
  • According to the latest figures from Q3 2025, AbbVie's EBIAT is $188.0 million, which was down 8797.95% from $941.0 million recorded in Q2 2025.
  • AbbVie's EBIAT's 5-year high stood at $4.5 billion during Q1 2022, with a 5-year trough of -$22.0 million in Q4 2024.
  • Over the past 5 years, AbbVie's median EBIAT value was $1.4 billion (recorded in 2024), while the average stood at $1.8 billion.
  • Its EBIAT has fluctuated over the past 5 years, first soared by 1113333.33% in 2021, then plummeted by 10267.64% in 2024.
  • Over the past 5 years, AbbVie's EBIAT (Quarter) stood at $4.0 billion in 2021, then crashed by 38.85% to $2.5 billion in 2022, then plummeted by 66.76% to $822.0 million in 2023, then plummeted by 102.68% to -$22.0 million in 2024, then skyrocketed by 954.55% to $188.0 million in 2025.
  • Its EBIAT stands at $188.0 million for Q3 2025, versus $941.0 million for Q2 2025 and $1.3 billion for Q1 2025.